Codexis, Inc.

NASDAQ:CDXS

Biotechnology

Healthcare
$1.15 +0.60%

+$0.02 today

Market cap
$126.04M
Beta
2.48
P/E (TTM)
-7.1
EPS (TTM)
-$0.35
52W Low $0.96High $3.87

Volume 1.47M

Average 1.15M

CDXS Short-term Debt

Borrowings and the current portion of long-term debt due within one year.

Codexis, Inc.NASDAQ: CDXS

Short-term Debt · Q1 FY2026 · quarter ended Mar 2026

Short-term debt remains negative

Q1 FY2026 short-term debt was $3.3M, compared with $0 a year earlier.

Context

  • Short-term debt amounted to 2.6% of total assets at the end of Q1 FY2026, up 2.6 pp from a year earlier.
  • Short-term debt increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$3.3M— QoQ
Last fiscal yearDec 2025
$0— YoY
Year agoMar 2025
$0— since
Short-term Debt past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Short-term Debt history

USD · from the balance sheet

Latest · FY2025
0 USD
Year-over-year change
—

Short-term Debt vs competitors

How CDXS compares with its peers on the latest reported figures

  • Peers report in different currencies, so short-term debt is compared through growth and share of total assets rather than absolute size.
  • Short-term debt amounts to 2.6% of total assets for CDXS, versus a peer median of 0.0%.
CDXS Competitors
Short-term Debt for CDXS and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
IPHAInnate Pharma S.A.Dec 2025€8.52M EUR+0.9%+88.9%13.6%
CCCCC4 Therapeutics, Inc.Mar 2026$6.52M USD——2.0%
OABIOmniAb, Inc.Mar 2026$3.94M USD——1.3%
CDXSCodexis, Inc.Mar 2026$3.3M USD——2.6%
IVVDInvivyd, Inc.Mar 2026$0 USD——0.0%
TARAProtara Therapeutics, Inc.Mar 2026$0 USD——0.0%
ARMPArmata Pharmaceuticals, Inc.Mar 2026$0 USD-100.0%—0.0%
IMDXInsight Molecular Diagnostics Inc.Mar 2026$0 USD——0.0%
RANIRani Therapeutics Holdings, Inc.Mar 2026$0 USD-100.0%—0.0%
SGMOSangamo Therapeutics, Inc.Mar 2026$0 USD——0.0%
Peer median (excluding CDXS) —-100.0%+88.9%0.0%

Competitors are the stored peer set for CDXS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents116.8M113.98M65.12M19.26M50.79M
Short-term Investments00054.19M27.42M
Net Receivables37.65M40.87M19.93M18.88M10.73M
Inventory1.16M2.03M2.69M1.8M1.82M
Other Current Assets579K521K5.74M4.63M6.06M
Total Current Assets161.89M162.89M93.47M98.77M96.82M
Property, Plant & Equipment (Net)65.46M61.88M28.62M42.9M43.53M
Goodwill3.24M3.24M2.46M2.46M2.46M
Intangible Assets00000
Long-term Investments14M20.51M9.7M2.8M2.5M
Tax Assets00000
Other Non-current Assets1.8M1.87M2.31M2.08M2.5M
Total Non-current Assets84.5M87.5M43.1M50.24M50.98M
Total Assets246.38M250.39M136.56M149.01M147.8M
Account Payables3M3.25M5.95M2.84M1.55M
Short-term Debt00000
Tax Payables00000
Deferred Revenue2.59M13.73M10.12M350K7.01M
Other Current Liabilities11.12M11.45M11.25M11.41M11.04M
Total Current Liabilities33.37M49.07M35.83M23.65M25.32M
Long-term Debt00028.91M40.11M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)3.75M16.88M640K100K360K
Other Non-current Liabilities1.31M1.37M1.23M1.27M1.33M
Total Non-current Liabilities48.62M56.53M14.12M58.44M71.95M
Total Liabilities81.99M105.6M49.95M82.08M97.27M
Common Stock6K6K7K8K9K
Retained Earnings(387.7M)(421.29M)(497.53M)(562.81M)(606.78M)
Accumulated OCI00052K8K
Other Stockholders Equity00000
Minority Interest00000
Total Equity164.39M144.8M86.62M66.93M50.53M
Total Debt47.65M43.64M16.02M59.9M73.21M
Net Debt(69.14M)(70.35M)(49.09M)40.63M22.42M

Codexis, Inc.

NASDAQ:CDXS

Intrinsic Alpha fair value

Locked

Current Price

$1.15

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.